BioPharma Services has acquired human resource assets along with a list of validated assays from Bioanalytical Laboratory Services (BLS). Over the past 3 years, BLS, led by lab director Nicola Hughes, has built a leading bioanalytical research center specializing in complex method development, method validation and the analysis of biological samples for pre-clinical and clinical drug trials (BA/BE studies). BLS assets will be combined with BioPharma’s existing bioanalytical lab to further expand and fortify its analytical services and become a global leader in clinical research.

“We are very proud to combine the best of BioPharma’s existing bioanalytical lab with the best of BLS. Under the scientific leadership of Dr. Hughes, the expanded lab at BioPharma will be able to immediately offer challenging and complex new assays while strengthening our scientific R&D team. This is just one of a list of benefits associated with merging the assets of two great labs at BioPharma,” said Renzo DiCarlo, chief executive officer, BioPharma Services.

Effective immediately, Dr. Hughes will be appointed to the BioPharma executive team as the vice president of lab operations.

With this news, existing BLS client projects will be honored and completed as planned at the current BLS facility. Anna Taylor, vice president of business development reiterated, “We truly are a client centered organization driven by science and quality research. I am excited that we have this opportunity to share our expanded BA lab expertise and service for both past and future clients under this new team at BioPharma.”